In numerous medical disorders, the disease manifests by increased apoptosis in the involved tissues. Some of these conditions could be treated by selective delivery of a drug directly to these tissues, using the apoptotic cells as targets.
This family of compounds is named ATT (Apoptosis Targeted Therapy)
Aposense has developed a novel class of small molecular probes that target cells undergoing apoptosis. Utilizing the modular structure of the Aposense probes, a specific drug of interest can be attached to their core structure, using it as a vector to target and concentrate such a drug-carrier complex to apoptotic tissues.
At the same time the Aposense probe helps reduce toxicity by avoiding interaction with healthy tissues.
The combined effect is expansion of the therapeutic window of the parent drug, through higher concentration in the target tissue and no interaction with healthy cells.
In addition, through high affinity to cell membranes, ATT molecules can achieve improved pharmacokinetic profile for the combined drug; High residence time in blood plasma and body tissues, creating a “depot” from which the drug is slowly released. This quality results in stable plasma levels, increased effectiveness period and reduced intake burden.
[18F]-ML-10 is an investigational agent, not yet approved for use outside clinical trials